Literature DB >> 29572889

Risk factors for diagnostic delay in Crohn's disease and their impact on long-term complications: how do they differ in a tuberculosis endemic region?

R Banerjee1, P Pal1, B G Girish1, D N Reddy1.   

Abstract

BACKGROUND: The diagnosis of Crohn's disease (CD) can be delayed in clinical practice. In tuberculosis endemic areas, empirical anti-tubercular therapy further delays treatment. AIM(S): To assess risk factors for diagnostic delay and its impact on the long-term complications of Crohn's disease in India where tuberculosis is endemic.
METHODS: Data from a large prospectively established inflammatory bowel disease registry were analysed retrospectively. The time from onset of symptoms to diagnosis (diagnostic delay) was calculated and categorised into two groups based on median diagnostic delay. The risk factors for delay including anti-tubercular therapy were analysed. Logistic regression analysis was done to assess impact of diagnostic delay on development of stenotic and fistular complications including need for surgery.
RESULTS: Seven hundred and twenty Crohn's disease patients (60.3% male, median: 28 years) were included. Main outcome measures were stenosis, fistula and need for surgery. Subjects with diagnostic delay >18 months (median) developed significantly higher stenotic complications and surgery (OR 4.12; 95% CI: 2.74-6.33, P < 0.001 and OR 2.41, 95% CI: 1.68-3.42, P < 0.001), respectively, compared to those ≤18 months. There was no difference in the development of fistulous complications. 193/720 (27%) received anti-tubercular therapy which significantly contributed to diagnostic delay (OR: 2.47; 95% CI: 1.76-3.47, P < 0.001) with 47% showing initial clinical response (Crohn's disease activity index- CDAI decrease >100). Moreover, the incidence of stenotic complications was significantly higher in patients who had received prior anti-tubercular therapy (55/193 (28.49%) vs 78/527 (14.8%), P < 0.001, OR: 2.60, 95% CI: 1.64-4.12).
CONCLUSIONS: Diagnostic delay in Crohn's disease is associated with significantly higher stenotic complications and need for surgery. Empirical anti-tubercular therapy is the single largest contributor to diagnostic delay in tuberculosis endemic areas. Despite initial clinical response to anti-tubercular therapy, long-term stenotic complications are higher.
© 2018 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2018        PMID: 29572889     DOI: 10.1111/apt.14617

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  10 in total

1.  Inflammatory bowel disease in India: challenges and opportunities.

Authors:  Alice Snell; Jonathan Segal; Jimmy Limdi; Rupa Banerjee
Journal:  Frontline Gastroenterol       Date:  2020-07-14

2.  Diagnostic Delay of Inflammatory Bowel Disease Is Significantly Higher in Public versus Private Health Care System in Mexican Patients.

Authors:  Jesús K Yamamoto-Furusho; Norma N Parra-Holguín
Journal:  Inflamm Intest Dis       Date:  2021-12-06

3.  Association of diagnostic delay with medical cost for patients with Crohn's disease: A Japanese claims-based cohort study.

Authors:  Eisuke Takeyama; Hiroo Wada; Setsuko Sato; Kiyohide Tomooka; Ai Ikeda; Takeshi Tanigawa
Journal:  JGH Open       Date:  2021-03-24

4.  Differentiation of intestinal tuberculosis and Crohn's disease through an explainable machine learning method.

Authors:  Futian Weng; Yu Meng; Fanggen Lu; Yuying Wang; Weiwei Wang; Long Xu; Dongsheng Cheng; Jianping Zhu
Journal:  Sci Rep       Date:  2022-02-02       Impact factor: 4.379

5.  IRW and IQW Reduce Colitis-Associated Cancer Risk by Alleviating DSS-Induced Colonic Inflammation.

Authors:  Yong Ma; Hongmei Jiang; Jun Fang; Gang Liu
Journal:  Biomed Res Int       Date:  2019-10-24       Impact factor: 3.411

6.  Intestinal tuberculosis or Crohn's disease: Illusion or delusion or allusion.

Authors:  Saurabh Kedia; Vineet Ahuja
Journal:  JGH Open       Date:  2021-02-03

7.  Validation of models using basic parameters to differentiate intestinal tuberculosis from Crohn's disease: A multicenter study from Asia.

Authors:  Julajak Limsrivilai; Choon Kin Lee; Piyapan Prueksapanich; Kamin Harinwan; Asawin Sudcharoen; Natcha Cheewasereechon; Satimai Aniwan; Pimsiri Sripongpan; Panu Wetwittayakhlang; Ananya Pongpaibul; Anapat Sanpavat; Nonthalee Pausawasdi; Phunchai Charatcharoenwitthaya; Peter D R Higgins; Siew Chien Ng
Journal:  PLoS One       Date:  2020-11-30       Impact factor: 3.240

Review 8.  Management of Crohn Disease: A Review.

Authors:  Kelly Cushing; Peter D R Higgins
Journal:  JAMA       Date:  2021-01-05       Impact factor: 157.335

Review 9.  Biologics for the Management of Inflammatory Bowel Disease: A Review in Tuberculosis-Endemic Countries.

Authors:  Rupa Banerjee; Raja Affendi Raja Ali; Shu Chen Wei; Shashi Adsul
Journal:  Gut Liver       Date:  2020-11-15       Impact factor: 4.519

10.  Factors associated with time to clinical remission in pediatric luminal Crohn's disease: A retrospective cohort study.

Authors:  Samuel Sassine; Souhila Zekhnine; Marwa Qaddouri; Lisa Djani; Christine Cambron-Asselin; Mathieu Savoie-Robichaud; Yi Fan Lin; Kelly Grzywacz; Véronique Groleau; Martha Dirks; Éric Drouin; Ugur Halac; Valérie Marchand; Chloé Girard; Olivier Courbette; Natalie Patey; Dorothée Dal Soglio; Colette Deslandres; Prévost Jantchou
Journal:  JGH Open       Date:  2021-11-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.